{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:12:26Z","timestamp":1781842346554,"version":"3.54.5"},"reference-count":102,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006380","name":"Universit\u00e4t f\u00fcr Bodenkultur Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["WO2020169577A1"],"award-info":[{"award-number":["WO2020169577A1"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.drudis.2025.104349","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T12:51:23Z","timestamp":1743684683000},"page":"104349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Are leukotrienes really the world\u2019s best bronchoconstrictors and at least 100 to 1000 times more potent than histamine?"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-0797","authenticated-orcid":false,"given":"Thomas","family":"Boehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104349_b0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1126\/science.7063880","article-title":"Bronchoconstrictor effects of leukotriene C in humans","volume":"216","author":"Weiss","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104349_b0010","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1001\/jama.1983.03330440052033","article-title":"Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy","volume":"249","author":"Weiss","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2025.104349_b0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/thx.39.7.500","article-title":"Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects","volume":"39","author":"Barnes","year":"1984","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2025.104349_b0020","first-page":"333","article-title":"Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects","volume":"135","author":"Davidson","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/ajrccm\/142.5.1112","article-title":"Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine, and histamine","volume":"142","author":"Arm","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM198302243080807","article-title":"Effects of leukotriene D on the airways in asthma","volume":"308","author":"Griffin","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104349_b0035","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1183\/09031936.93.06101468","article-title":"Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects","volume":"6","author":"Christie","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104349_b0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1164\/ajrccm\/144.5.1053","article-title":"Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways","volume":"144","author":"O\u2019Hickey","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0045","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1164\/ajrccm\/146.6.1531","article-title":"Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects","volume":"146","author":"Christie","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1164\/ajrccm.164.2.2101105","article-title":"Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma","volume":"164","author":"Echazarreta","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104349_b0055","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaci.2018.02.024","article-title":"Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor","volume":"142","author":"Lazarinis","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-5381.1986.tb11115.x","article-title":"Dissociation constants and relative efficacies of acetylcholine, (+)- and (-)-methacholine at muscarinic receptors in the guinea-pig ileum","volume":"89","author":"Ringdahl","year":"1986","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104349_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/08037059609078071","article-title":"Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm","volume":"5","author":"Bruning","year":"1996","journal-title":"Blood Press"},{"key":"10.1016\/j.drudis.2025.104349_b0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2222.2003.01696.x","article-title":"Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites","volume":"33","author":"Mechiche","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2025.104349_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fcell.2016.00103","article-title":"Evaluation of cysteinyl leukotriene signalling as a therapeutic target for colorectal cancer","volume":"4","author":"Burke","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2025.104349_b0080","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1073\/pnas.78.6.3887","article-title":"Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response","volume":"78","author":"Dahlen","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104349_b0085","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/288484a0","article-title":"Leukotrienes are potent constrictors of human bronchi","volume":"288","author":"Dahlen","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104349_b0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-6749(82)80005-5","article-title":"Effects of infused histamine: correlation of plasma histamine levels and symptoms","volume":"69","author":"Kaliner","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF01980899","article-title":"Plasma histamine and clinical tolerance to infused histamine in normal, atopic and urticarial subjects","volume":"32","author":"Pollock","year":"1991","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2025.104349_b0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/bja\/65.6.833","article-title":"Massive histamine release in a patient with systemic mastocytosis","volume":"65","author":"Desborough","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.drudis.2025.104349_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(06)80017-5","article-title":"Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation","volume":"90","author":"Van der Linden","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1148\/radiology.209.1.9769830","article-title":"Mechanisms of severe, immediate reactions to iodinated contrast material","volume":"209","author":"Laroche","year":"1998","journal-title":"Radiology"},{"key":"10.1016\/j.drudis.2025.104349_b0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/ALN.0000000000000276","article-title":"Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia","volume":"121","author":"Laroche","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2025.104349_b0120","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/ALN.0000000000001600","article-title":"In vivo cysteinyl leukotriene release in allergic and nonallergic immediate hypersensitivity reactions during anesthesia","volume":"126","author":"Laroche","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2025.104349_b0125","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaci.2021.03.043","article-title":"Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis","volume":"148","author":"Boehm","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0130","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2022.04.023","article-title":"Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis","volume":"150","author":"Boehm","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0135","doi-asserted-by":"crossref","first-page":"16477","DOI":"10.1074\/jbc.M705822200","article-title":"Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells","volume":"283","author":"Paruchuri","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104349_b0140","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2007-07-100453","article-title":"CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells","volume":"110","author":"Jiang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104349_b0145","unstructured":"Boehm T, Jilma B. How effective are histamine receptor antagonists in the treatment of histamine-driven clinical symptoms? Do we have a histamine or better an anti-histamine problem? Drug Discov Today (in preparation)."},{"key":"10.1016\/j.drudis.2025.104349_b0150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.2042-7158.1973.tb09942.x","article-title":"The tautomer ratio of histamine","volume":"25","author":"Ganellin","year":"1973","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2025.104349_b0155","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two decades under the influence of the rule of five and the changing properties of approved oral drugs","volume":"62","author":"Shultz","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104349_b0160","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/mp9000662","article-title":"Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery","volume":"6","author":"Peetla","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2025.104349_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183781","article-title":"What can we learn about amphiphile-membrane interaction from model lipid membranes?","volume":"1864","author":"Fanani","year":"2022","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.drudis.2025.104349_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.drudis.2025.104349_b0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2025.104349_b0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0005-2736(81)90401-6","article-title":"Histamine, theophylline and tryptamine transport through lipid bilayer membranes","volume":"649","author":"Gutknecht","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2025.104349_b0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0169-409X(90)90006-E","article-title":"The absorption and metabolism of xenobiotics in the lung","volume":"5","author":"Taylor","year":"1990","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.drudis.2025.104349_b0190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2009.05.046","article-title":"The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications","volume":"124","author":"Austen","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0195","first-page":"19","article-title":"The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction","volume":"126","author":"Joris","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2025.104349_b0200","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0091-6749(05)80180-0","article-title":"Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects","volume":"86","author":"Maxwell","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/1523-1747.ep12265527","article-title":"Leukotriene- and histamine-induced increases in vascular permeability and interstitial transport in the skin","volume":"84","author":"Bisgaard","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104349_b0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1523-1747.ep12531738","article-title":"Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin","volume":"80","author":"Soter","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2025.104349_b0215","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4049\/jimmunol.182.2.1129","article-title":"P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells","volume":"182","author":"Jiang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0220","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1084\/jem.20091240","article-title":"Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor","volume":"206","author":"Paruchuri","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104349_b0225","doi-asserted-by":"crossref","first-page":"20461","DOI":"10.1038\/srep20461","article-title":"Leukotriene E4 is a full functional agonist for human cysteinyl leukotriene type 1 receptor-dependent gene expression","volume":"6","author":"Foster","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104349_b0230","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4049\/jimmunol.1102474","article-title":"Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2","volume":"188","author":"Xue","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1172\/JCI110670","article-title":"Generation of leukotrienes by purified human lung mast cells","volume":"70","author":"MacGlashan","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104349_b0240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molimm.2014.05.007","article-title":"Functional characterization of histamine H4 receptor on human mast cells","volume":"62","author":"Jemima","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0245","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1139\/y95-028","article-title":"Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist","volume":"73","author":"Jones","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2025.104349_b0250","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.drudis.2025.104349_b0255","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1398-9995.2007.01364.x","article-title":"PGE suppresses excessive anti-IgE induced cysteinyl leukotrienes production in mast cells of patients with aspirin exacerbated respiratory disease","volume":"62","author":"Wang","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2025.104349_b0260","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.4049\/jimmunol.131.4.1936","article-title":"Heterogeneity of human mast cells","volume":"131","author":"Schulman","year":"1983","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0265","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.133.4.2138","article-title":"Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release","volume":"133","author":"Holgate","year":"1984","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0270","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.4049\/jimmunol.132.4.1972","article-title":"Arachidonic acid metabolism in purified human lung mast cells","volume":"132","author":"Peters","year":"1984","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0275","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4049\/jimmunol.135.1.483","article-title":"Isolation and characterization of human intestinal mucosal mast cells","volume":"135","author":"Fox","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0280","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.4049\/jimmunol.139.9.3062","article-title":"Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity","volume":"139","author":"Lawrence","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0285","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1476-5381.1989.tb12030.x","article-title":"Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli","volume":"97","author":"Benyon","year":"1989","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104349_b0290","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0005-2760(95)00048-H","article-title":"Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene expression and biosynthesis of thromboxane","volume":"1257","author":"Macchia","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2025.104349_b0295","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bja.2020.08.024","article-title":"Societe Francaise d\u2019Anesthesie et Reanimation (SFAR) Research Network. Epidemiology and outcome of patients admitted to intensive care after anaphylaxis in France: a retrospective multicentre study","volume":"125","author":"Guerci","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.drudis.2025.104349_b0300","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archinte.161.1.15","article-title":"Anaphylaxis in the United States: an investigation into its epidemiology","volume":"161","author":"Neugut","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.drudis.2025.104349_b0305","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0065-2571(89)90078-2","article-title":"Metabolic inactivation of leukotrienes","volume":"28","author":"Keppler","year":"1989","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.drudis.2025.104349_b0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eclinm.2018.07.002","article-title":"Investigators of the CIRTACI study. Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI study","volume":"1","author":"Clement","year":"2018","journal-title":"EclinicalMedicine"},{"key":"10.1016\/j.drudis.2025.104349_b0315","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000542-198109000-00028","article-title":"Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine","volume":"55","author":"Fahmy","year":"1981","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2025.104349_b0320","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1213\/00000539-199809000-00036","article-title":"Oral antihistamines reduce the side effects from rapid vancomycin infusion","volume":"87","author":"Renz","year":"1998","journal-title":"Anesth Analg"},{"key":"10.1016\/j.drudis.2025.104349_b0325","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/BF01716946","article-title":"Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: studies in the conscious human subject","volume":"60","author":"Lorenz","year":"1982","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.drudis.2025.104349_b0330","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/all.13663","article-title":"Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients","volume":"74","author":"Boehm","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2025.104349_b0335","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2222.1983.tb02568.x","article-title":"Measurement of plasma histamine in asthma","volume":"13","author":"Ind","year":"1983","journal-title":"Clin Allergy"},{"key":"10.1016\/j.drudis.2025.104349_b0340","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0091-6749(77)90111-7","article-title":"The relationship of plasma histamine to the activity of bronchial asthma","volume":"60","author":"Simon","year":"1977","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0345","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1042\/cs0620661","article-title":"Plasma histamine and catecholamines in stable asthmatic subjects","volume":"62","author":"Barnes","year":"1982","journal-title":"Clin Sci (lond)"},{"key":"10.1016\/j.drudis.2025.104349_b0350","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/0091-6749(80)90009-3","article-title":"Comparison of plasma histamine and cyclic nucleotides after antigen and methacholine inhalation in man","volume":"66","author":"Atkins","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0355","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0091-6749(91)90158-K","article-title":"Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway","volume":"88","author":"Broide","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01973821","article-title":"Histamine content, diamine oxidase activity and histamine methyltransferase activity in human tissues: fact or fictions?","volume":"14","author":"Hesterberg","year":"1984","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2025.104349_b0365","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1164\/ajrccm\/142.1.112","article-title":"Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge","volume":"142","author":"Wenzel","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0370","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3390\/biomedicines10112845","article-title":"Urinary cysteinyl leukotrienes as biomarkers of endothelial activation, inflammation and oxidative stress and their relationship with organ dysfunction in human septic shock","volume":"10","author":"Reina-Couto","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104349_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3454212","article-title":"Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases","volume":"2017","author":"Gelosa","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.drudis.2025.104349_b0380","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI114051","article-title":"Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis","volume":"83","author":"Schwartz","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104349_b0385","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"1","author":"Ring","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104349_b0390","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2025.104349_b0395","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/0006-291X(87)90955-7","article-title":"The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals","volume":"148","author":"Verhagen","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104349_b0400","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0006-291X(85)90404-8","article-title":"In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4","volume":"130","author":"Oerning","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104349_b0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0091-6749(90)90214-O","article-title":"Leukotriene C4 elimination and metabolism in man","volume":"85","author":"Maltby","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1183\/09031936.00093407","article-title":"Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia","volume":"32","author":"Ono","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104349_b0415","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0420","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1183\/09031936.94.07050907","article-title":"Increased urinary LTE4 excretion following inhalation of LTC4 and LTE4 in asthmatic subjects","volume":"7","author":"Christie","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104349_b0425","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0954-6111(03)00253-1","article-title":"High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma","volume":"97","author":"Vachier","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.drudis.2025.104349_b0430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1164\/rccm.201909-1869OC","article-title":"U-BIOPRED Study Group, on behalf of the U-BIOPRED Study Group. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study","volume":"203","author":"Kolmert","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104349_b0435","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(89)91611-5","article-title":"Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis","volume":"1","author":"Taylor","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104349_b0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0091-6749(05)80068-5","article-title":"Urinary leukotriene E4 levels during early and late asthmatic responses","volume":"86","author":"Manning","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0445","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/rccm.200208-802OC","article-title":"A randomized controlled trial of intravenous montelukast in acute asthma","volume":"167","author":"Camargo","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104349_b0450","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaci.2009.11.015","article-title":"A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma","volume":"125","author":"Camargo","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0455","unstructured":"Singulair (montelukast) prescription information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021409s036lbl.pdf."},{"key":"10.1016\/j.drudis.2025.104349_b0460","unstructured":"Accolate (zafirlukast) prescription information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020547s033lbl.pdf."},{"key":"10.1016\/j.drudis.2025.104349_b0465","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.drudis.2025.104349_b0470","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-130-6-199903160-00005","article-title":"Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast\/Beclomethasone Study Group","volume":"130","author":"Malmstrom","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.drudis.2025.104349_b0475","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0091-6749(96)70086-6","article-title":"Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma","volume":"98","author":"Reiss","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0480","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0091-6749(98)70054-5","article-title":"A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group","volume":"102","author":"Altman","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104349_b0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2040622310383343","article-title":"Montelukast in asthma: a review of its efficacy and place in therapy","volume":"2","author":"Paggiaro","year":"2011","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.drudis.2025.104349_b0490","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1023\/A:1016056912698","article-title":"Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females","volume":"13","author":"Cheng","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2025.104349_b0495","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.1780140503","article-title":"Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation","volume":"14","author":"Kushner","year":"1971","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104349_b0500","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0026-2862(74)90035-1","article-title":"Effects of histamine and some other substances on molecular selectivity of the capillary wall to plasma proteins and dextran","volume":"7","author":"Carter","year":"1974","journal-title":"Microvasc Res"},{"key":"10.1016\/j.drudis.2025.104349_b0505","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68542","article-title":"Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical","volume":"10","author":"Gludovacz","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104349_b0510","unstructured":"GINA Pocket Guide for Asthma Management and Prevention. 2023. https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/07\/GINA-2023-Pocket-Guide-WMS.pdf."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:17:16Z","timestamp":1758125836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1359644625000625"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104349","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are leukotrienes really the world\u2019s best bronchoconstrictors and at least 100 to 1000 times more potent than histamine?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104349"}}